Literature DB >> 18224416

An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis.

Yuriko Morita-Hoshi1, Shuji Tohda, Osamu Miura, Nobuo Nara.   

Abstract

It is quite rare to diagnose interstitial nephritis and secondary amyloidosis during the course of Castleman's disease (CD). To our knowledge, only four cases of interstitial nephritis and 44 cases of amyloidosis associated with CD have been reported to date. A 51-year-old man with a 9-year history of hypergammaglobulinemia was diagnosed with multicentric Castleman's disease of the plasma cell type. At the age of 55, it was complicated with interstitial nephritis, which was successfully treated with steroids and cyclophosphamide. At the age of 58, he was diagnosed with secondary AA amyloidosis and thrombocytopenia, which led to a fatal brain hemorrhage. The plasma cell type of this illness involves a relatively high incidence of amyloidosis, and the present patient suggests that some cases of multicentric Castleman's disease could proceed rapidly, be unresponsive to steroid therapy, and may have a fatal outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18224416     DOI: 10.1007/s12185-007-0015-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  38 in total

1.  Castleman's disease with nephrotic syndrome, amyloidosis and autoimmune manifestations.

Authors:  S Curioni; M D'Amico; R Quartagno; S Martino; G Dell'Antonio; D Cusi
Journal:  Nephrol Dial Transplant       Date:  2001-07       Impact factor: 5.992

2.  Castleman's disease with renal infiltration by polyclonal plasma cells.

Authors:  O Frøkjaer Thomsen; J Ladefoged
Journal:  Clin Nephrol       Date:  1998-05       Impact factor: 0.975

3.  Castleman's disease with renal amyloidosis and nephrotic syndrome.

Authors:  T Arinsoy; M Yilmaz; O Ataoğlu; M Bali; S Sindel
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

4.  Angiofollicular lymph node hyperplasia with amyloidosis.

Authors:  K P West; D R Morgan; I Lauder
Journal:  Postgrad Med J       Date:  1989-02       Impact factor: 2.401

5.  Mesenteric hyaline plasma cell lymph node hyperplasia with amyloid deposits.

Authors:  J Garcia-SanMiguel; C Rozman; A Palacin; B Nomdedeu
Journal:  Arch Intern Med       Date:  1981-02

6.  Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease.

Authors:  S Paydas; G Gonlusen; Y Sagliker
Journal:  Nephron       Date:  1995       Impact factor: 2.847

7.  Castleman disease and renal amyloidosis.

Authors:  I Kazes; G Deray; C Jacobs
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

8.  Systemic amyloidosis associated with a benign mesenteric lymphoid mass.

Authors:  V A Pilon; L G Gomez; J J Butler
Journal:  Am J Clin Pathol       Date:  1982-07       Impact factor: 2.493

9.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

Review 10.  Localized Castleman's disease and nephrotic syndrome not responsive to resection plus colchicine therapy.

Authors:  U Derici; T Arinsoy; O Ataoglu; M Bali; A Eroglu; B Goker; S Sindel
Journal:  Ann Hematol       Date:  2002-06-25       Impact factor: 3.673

View more
  2 in total

1.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome.

Authors:  Tamami Fujiki; Suguru Hirasawa; Seishi Watanabe; Shunsuke Iwamoto; Ryoichi Ando
Journal:  CEN Case Rep       Date:  2017-03-07

Review 2.  AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Authors:  Luca Bernabei; Adam Waxman; Gabriel Caponetti; David C Fajgenbaum; Brendan M Weiss
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.